Clinical trials: Infections, Streptococcal
Tonsillitis
A Multicenter, Randomized, Double-Blind, Double-Dummy Study Of Azithromycin SR Versus Amoxicillin For The Treatment Of Strep Throat In Children
The objective was to determine if a single 60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin (45 mg/kg/day, given in divided doses every 12 hours) when used to treat children with strep…
- Trial name
- NCT00643149
- Testing
- amoxicillin, azithromycin SR
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 693 people
- Sponsor
- Pfizer
Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit…
- Trial name
- NCT07365826
- Testing
- 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok)
- Where
- 25 sites in United States
- Volunteers
- 1,390 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)
This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults infected with HIV and to 2) describe the safety, tolerability, and immunogenicity of…
- Trial name
- PNEU-WAY (NCT03480802)
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Disease
Pneumoniae Epidemiology Study in China
To determine the proportion of hospitalized pneumonia cases in children aged 60 months or less associated with vaccine-preventable Streptococcus pneumoniae serotypes (4, 6B, 9V, 14, 18C, 19F, 23F).
- Trial name
- NCT00471770
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections
Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47
The main aim of this clinical study is to investigate the safety and tolerability of different dose strengths of IC47 up to 6 months after the first vaccination.
- Trial name
- NCT00873431
- Testing
- IC47
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Streptococcus Pneumoniae
Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine
GEN-004 is a combination of 3 conserved proteins from Streptococcus pneumoniae. This is a randomized, double-blind, placebo-controlled, dose escalation study.
- Trial name
- NCT01995617
- Testing
- GEN-004 Low Dose, GEN-004 Low Dose + Adjuvant, GEN-004 Mid Dose
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Genocea Biosciences, Inc.
Strep Throat
Preview Rapid Strep A Test Method Comparison Study
This study is designed to determine the accuracy of the Preview Rapid Strep A Test compared to a laboratory reference method for Group A Streptococcal infection and to determine the precision of the Preview Rapid Strep A test.
- Trial name
- NCT03907449
- Testing
- Preview Rapid Strep A test
- Where
- 2 sites in United States
- Volunteers
- 320 people
- Sponsor
- Guangzhou Wondfo Biotech Co., Ltd
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the GSK Biologicals' pneumococcal vaccine 2830930A in toddlers aged 12 to 23 months at study entry.
- Trial name
- NCT01485406
- Testing
- Pneumococcal vaccine GSK2830930A, Synflorix™
- Where
- 4 sites in Germany
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Pneumococcal Infections
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous…
- Trial name
- NCT02583373
- Testing
- CAL02 Low-dose, CAL02 High-dose
- Where
- 10 sites in Belgium, France
- Volunteers
- 19 people
- Sponsor
- Combioxin SA
Pneumococcal Disease
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.
- Trial name
- NCT06044077
- Testing
- 23-valent pneumococcal polysaccharide vaccine, control pneumococcal polysaccharide vaccine
- Where
- China
- Volunteers
- 1,920 people, healthy volunteers welcome
- Sponsor
- Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Impetigo
Fucidin® Cream in the Treatment of Impetigo
To investigate the clinical and bacteriological efficacy of Fucidin® cream in the treatment of impetigo in paediatric patients. To assess the validity of in vitro susceptibility-testing of S.
- Trial name
- NCT00986856
- Testing
- Fucidin® cream
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 58 people
- Sponsor
- LEO Pharma
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)
This study is designed to describe the safety, tolerability, and immunogenicity of V114 in children with sickle cell disease.
- Trial name
- NCT03731182
- Testing
- V114, Prevnar 13™
- Where
- 19 sites in United States, Brazil and 5 more
- Volunteers
- 104 people
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
A vaccine called Prevenar is already approved for use in China for vaccination of children younger than 6 years old against infections caused by Streptococcus pneumoniae.
- Trial name
- 6114A1-4000-CN (NCT01193582)
- Testing
- Prevenar
- Where
- 5 sites in China
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal
Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose
This primary purpose of this study is the evaluation of the immunological persistence following completion of the 3-dose primary vaccination course with either a clinical or a commercial lot of pneumococcal conjugate vaccine…
- Trial name
- NCT01119625
- Testing
- Pneumococcal vaccine GSK1024850A, Infanrix-IPV/Hib
- Where
- 3 sites in Singapore
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Pneumococcal, Diabetes Mellitus
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
Primary care visits are a key aspect of clinical care focused on helping patients to close care gaps related to preventive care such as vaccination, diabetes testing, statin therapy and cancer screening.
- Conditions
- Pneumonia, Pneumococcal, Diabetes Mellitus, Breast Cancer, Colorectal Cancer
- Trial name
- NCT05799976
- Testing
- Text message nudge
- Where
- United States
- Volunteers
- 29,334 people, healthy volunteers welcome
- Sponsor
- Mitesh Patel
Streptococcus Pneumoniae Infections
Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China
This study is to observe the carriage rate of Streptococcus pneumoniae (S.p.), Haemophilus influenzae Type B (Hib) and Moraxella catarrhalis (M.Cat.) in healthy Chinese children aged 12-18 months in order to estimate the…
- Trial name
- NCT00952367
- Testing
- Nasopharyngeal swab
- Where
- 6 sites in China
- Volunteers
- 3,641 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants Aged 2-23 Months
A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.
- Trial name
- NCT06800261
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Infections
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
This is a Phase 2, randomized, double-blinded study with a 2-arm parallel design. Healthy adults aged 60 through 64 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single…
- Trial name
- NCT03313037
- Testing
- Multivalent, Prevnar 13, PPSV23
- Where
- 14 sites in United States
- Volunteers
- 444 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan
Streptococcus pneumoniae is a major cause of pneumonia, among infants and children in Japan and worldwideThis study plans to investigate the rate of invasive pneumococcal disease "IPD " and the rate of hospitalizations due to…
- Trial name
- NCT00757575
- Where
- 2 sites in Japan
- Volunteers
- 28,511 people
- Sponsor
- Pfizer
Sore Throat, Pharyngitis
APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat
The primary objective of this study is to evaluate the efficacy of APC 111 MP Tablet, 775 mg tablet, given orally (PO)once daily (QD) for 10 days compared to that of Penicillin VK, 250 mg PO four times daily (QID) for 10 days in…
- Conditions
- Sore Throat, Pharyngitis, Tonsillitis
- Trial name
- NCT00242281
- Testing
- APC-111 MP Tablet, 775 mg
- Where
- 41 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Advancis Pharmaceutical Corporation